BACKGROUND: The Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) trial enrolled 1161 patients admitted to the hospital for acute heart failure (AHF) to evaluate the therapeutic efficacy of serelaxin, a recombinant form of human relaxin-2. We characterized how representative RELAX-AHF clinical trial enrollees were to those patients with AHF found in international registries. METHODS AND RESULTS: We examined 196 770 AHF admissions from the Acute Decompensated Heart Failure National Registry-United States and Acute Decompensated Heart Failure National Registry-International registries. Patients were considered RELAX-AHF-type if they met the following criteria: discharge diagnosis of heart failure, systolic blood pressure >125 mmHg, dyspnea at rest or with mild exertion, intravenous diuretic use, glomerular filtration rate of 30 to 75 mL/min per 1.73 m(2), hemoglobin >8 g/dL, and no use of intravenous inotropes or vasopressors. Baseline characteristics and treatments of RELAX-AHF-type and non-RELAX-AHF-type patients were compared. A Cox model was used to evaluate inpatient mortality. Among both Acute Decompensated Heart Failure National Registry-United States and Acute Decompensated Heart Failure National Registry-International registries, 20.7% (n=38 485) and 16.2% (n=1749) of patients met basic criteria for RELAX-AHF entry, respectively. These patients were more likely to be older, be women, have a previous history of hypertension, have preserved ejection fraction, and have better renal function. In-hospital mortality was lower in RELAX-AHF-type than in non-RELAX-AHF-type patients, even after multivariable adjustment (hazard ratio, 0.59; 95% confidence interval, 0.53-0.66; P<0.0001). CONCLUSIONS:Patients potentially eligible for RELAX-AHF represent ≈2 in 10 patients with AHF in the United States, Latin America, or Asia-Pacific. These patients differ significantly from other hospitalized patients based on clinical characteristics and outcomes.
RCT Entities:
BACKGROUND: The Relaxin for the Treatment of Acute Heart Failure (RELAX-AHF) trial enrolled 1161 patients admitted to the hospital for acute heart failure (AHF) to evaluate the therapeutic efficacy of serelaxin, a recombinant form of humanrelaxin-2. We characterized how representative RELAX-AHF clinical trial enrollees were to those patients with AHF found in international registries. METHODS AND RESULTS: We examined 196 770 AHF admissions from the Acute Decompensated Heart Failure National Registry-United States and Acute Decompensated Heart Failure National Registry-International registries. Patients were considered RELAX-AHF-type if they met the following criteria: discharge diagnosis of heart failure, systolic blood pressure >125 mm Hg, dyspnea at rest or with mild exertion, intravenous diuretic use, glomerular filtration rate of 30 to 75 mL/min per 1.73 m(2), hemoglobin >8 g/dL, and no use of intravenous inotropes or vasopressors. Baseline characteristics and treatments of RELAX-AHF-type and non-RELAX-AHF-type patients were compared. A Cox model was used to evaluate inpatient mortality. Among both Acute Decompensated Heart Failure National Registry-United States and Acute Decompensated Heart Failure National Registry-International registries, 20.7% (n=38 485) and 16.2% (n=1749) of patients met basic criteria for RELAX-AHF entry, respectively. These patients were more likely to be older, be women, have a previous history of hypertension, have preserved ejection fraction, and have better renal function. In-hospital mortality was lower in RELAX-AHF-type than in non-RELAX-AHF-type patients, even after multivariable adjustment (hazard ratio, 0.59; 95% confidence interval, 0.53-0.66; P<0.0001). CONCLUSIONS:Patients potentially eligible for RELAX-AHF represent ≈2 in 10 patients with AHF in the United States, Latin America, or Asia-Pacific. These patients differ significantly from other hospitalized patients based on clinical characteristics and outcomes.
Authors: Òscar Miró; Víctor Gil; Christian Müller; Alexander Mebazaa; Héctor Bueno; Francisco Javier Martín-Sánchez; Pablo Herrero; Javier Jacob; Pere Llorens Journal: Clin Res Cardiol Date: 2015-04-24 Impact factor: 5.460
Authors: Mauricio Velez; Edward L Peterson; Karen Wells; Tanmay Swadia; Hani N Sabbah; L Keoki Williams; David E Lanfear Journal: J Card Fail Date: 2014-10-28 Impact factor: 5.712
Authors: Anando Sen; Patrick B Ryan; Andrew Goldstein; Shreya Chakrabarti; Shuang Wang; Eileen Koski; Chunhua Weng Journal: Ann N Y Acad Sci Date: 2016-09-06 Impact factor: 5.691
Authors: Stephen J Greene; Adam D DeVore; Shubin Sheng; Gregg C Fonarow; Javed Butler; Robert M Califf; Adrian F Hernandez; Roland A Matsouaka; Ayman Samman Tahhan; Kevin L Thomas; Muthiah Vaduganathan; Clyde W Yancy; Eric D Peterson; Christopher M O'Connor; Robert J Mentz Journal: JACC Heart Fail Date: 2019-10-09 Impact factor: 12.035
Authors: Jindrich Spinar; Jiri Jarkovsky; Lenka Spinarova; Jiri Vitovec; Ales Linhart; Petr Widimsky; Roman Miklik; Kamil Zeman; Jan Belohlavek; Filip Malek; Cestmir Cihalik; Jiri Spac; Marian Felsoci; Petr Ostadal; Ladislav Dusek; Jiri Kettner; Jan Vaclavik; Simona Littnerova; Zdeněk Monhart; Josef Malek; Jiri Parenica Journal: ESC Heart Fail Date: 2016-09-17
Authors: Matthew T Mefford; Sandra Y Koyama; Justine De Jesus; Rong Wei; Heidi Fischer; Teresa N Harrison; Pauline Woo; Kristi Reynolds Journal: J Am Heart Assoc Date: 2022-03-24 Impact factor: 6.106